
USD
$0.00
(0.00%
)At Close (As of Dec 11, 2025)
$4.48B
Market Cap
51.45
P/E Ratio
2.55
EPS
$156.00
52 Week High
$55.00
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $262M |
| Total Revenue | $442M |
| Cost Of Revenue | $179M |
| Costof Goods And Services Sold | $179M |
| Operating Income | $37M |
| Selling General And Administrative | $169M |
| Research And Development | $56M |
| Operating Expenses | $225M |
| Investment Income Net | - |
| Net Interest Income | -$14M |
| Interest Income | - |
| Interest Expense | $14M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $20M |
| Income Before Tax | $36M |
| Income Tax Expense | $316K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $35M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $50M |
| Ebitda | $70M |
| Net Income | $35M |
| Field | Value (USD) |
|---|---|
| Total Assets | $804M |
| Total Current Assets | $497M |
| Cash And Cash Equivalents At Carrying Value | $337M |
| Cash And Short Term Investments | $337M |
| Inventory | $47M |
| Current Net Receivables | $98M |
| Total Non Current Assets | $307M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $2.2M |
| Intangible Assets Excluding Goodwill | $2.2M |
| Goodwill | $12M |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $16M |
| Other Non Current Assets | - |
| Total Liabilities | $575M |
| Total Current Liabilities | $60M |
| Current Accounts Payable | $10M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $2.7M |
| Total Non Current Liabilities | $516M |
| Capital Lease Obligations | $9M |
| Long Term Debt | $509M |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $518M |
| Other Current Liabilities | $45M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $229M |
| Treasury Stock | - |
| Retained Earnings | -$468M |
| Common Stock | $697M |
| Common Stock Shares Outstanding | $35M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $262M |
| Total Revenue | $442M |
| Cost Of Revenue | $179M |
| Costof Goods And Services Sold | $179M |
| Operating Income | $37M |
| Selling General And Administrative | $169M |
| Research And Development | $56M |
| Operating Expenses | $225M |
| Investment Income Net | - |
| Net Interest Income | -$14M |
| Interest Income | - |
| Interest Expense | $14M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $20M |
| Income Before Tax | $36M |
| Income Tax Expense | $316K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $35M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $50M |
| Ebitda | $70M |
| Net Income | $35M |
Sector: HEALTHCARE
Industry: MEDICAL DEVICES
TransMedics Group, Inc. (TMDX) is a pioneering medical technology firm based in Andover, Massachusetts, focused on revolutionizing organ transplant therapies for patients with end-stage organ failure. The company’s flagship product, the Organ Care System, optimizes the preservation and functionality of donor organs, leading to improved patient outcomes and extended transplant viability. As a commercial-stage company, TransMedics is well-positioned to capitalize on the growing global demand for organ transplants, providing innovative solutions that address significant challenges within the transplant ecosystem and aim to set new standards in organ care.